6月20日 - ** 富国银行给予药物开发商Metsera MTSR.O"增持 "评级
** 券商称MTSR在拥挤的肥胖症药物市场中脱颖而出，其资产有望实现按月给药和具有竞争力的疗效
** 富国银行："早期数据看起来很有希望，未来 12 个月内的一些数据将揭示这些资产的差异化竞争优势。
** 本月早些时候，Metsera 称其实验性药物在一项小型早期试验中帮助患者减轻了体重 (link)，显示出按月给药的潜力。
** 券商将目标价定为 65 美元，较上一交易日收盘价上涨约 134.6
** 截至上次收盘，该公司股票较 1 月份首次公开募股（(link)）时 18 美元的发行价上涨了约 53.9
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.